EUCTR2005-003319-64-GB进行中（未招募）1 期
A randomised, placebo-controlled, crossover study to measure the effect of alosetron on mucosal blood flow in female healthy volunteers and diarrhea-predominant IBS subjects - N/A
GlaxoSmithKline Research and Development Limited0 个研究点目标入组 0 人开始时间: 2006年3月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •A subject will be eligible for inclusion in this study only if all of the following criteria apply:
- •1.The subject signs and dates a written informed consent form prior to the initiation of any study-related activities.
- •2.The subject is between 18 and 65 years of age at the time of the Screening Visit.
- •3.The subject is female and either:
- •A healthy subject.
- •Healthy subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history (including family), physical examination, laboratory studies, and other tests.
- •A d-IBS patient per the Rome II criteria that has a normal result from a flexible sigmoidoscopy or colonoscopy, or flexible sigmoidoscopy plus barium enema, according to subject’s age, within 2 years of the Screening visit.
- •If the subject is <50 years of age, normal result from a flexible sigmoidoscopy or colonoscopy, or flexible sigmoidoscopy plus barium enema.
- •If the subject is =50 years of age, normal result from a colonoscopy or flexible sigmoidoscopy plus barium enema.
- •4.The subject demonstrates a negative urine pregnancy test result prior to investigational product administration and be either:
- •Of non-childbearing potential (i.e., physiologically incapable of becoming pregnant)
- •post-menopausal define as one year without menses in the absence of hormone replacement therapy.
- •sterilization (via hysterectomy or bilateral tubal ligation)
- •Of childbearing potential and agrees to one of the following acceptable non-hormonal contraceptive methods consistently and in accordance with both the product label and the instructions of a physician. Subjects will use effective contraceptive methods for at least one month prior to Screening and should continue to use the same contraceptive method throughout the study (Follow-up Visit).
- •Complete abstinence from intercourse
- •an intra-uterine device (IUD) inserted by a qualified physician, provided the IUD is not of the hormonal type and it has published data showing that the highest expected failure rate is less than 1% per year (not all IUDs meet this criterion)
- •double barrier method if comprised of a spermicide with either a condom or diaphragm
- •sterilization of partner
- •5.The subject is ambulatory (defined as not depending exclusively on a wheelchair for mobility).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- •1.The subject is taking oral contraceptive or other hormonal therapy.
- •2.The subject has a concurrent illness or disability that may affect the interpretation of clinical data, or otherwise contraindicates participation in this clinical study (e.g., an unstable cardiovascular, autoimmune, renal, hepatic, pulmonary, endocrine, metabolic, gastrointestinal, hematologic, or neurological condition).
- •3.The subject has constipation-predominant IBS (c-IBS) or alternating IBS per the ROME II criteria.
- •4.The subject has current evidence of or history of chronic or severe constipation, or a history of sequelae from constipation.
- •5.Evidence of a biochemical or structural abnormality of the digestive tract. These conditions include (but not limited to):
- •Current evidence, or history of (at any time in the past):
- •inflammatory bowel disease (Crohn's disease or ulcerative colitis)
- •celiac disease
- •laxative abuse (in the clinical judgement of the physician)
- •gastrointestinal surgery (exceptions include ?6 months post-surgery appendectomy, cholecystectomy, fundoplication without gas bloat, or hiatal hernia repair; ?3 months post-surgery herniorrhaphy without bowel resection)
- •gastroparesis
- •GI malignancy
- •carcinoid syndrome
- •amyloidosis
- •chronic pancreatitis
- •gastrointestinal adhesions
- •ischemic colitis
- •toxic megacolon
- •impaired intestinal circulation
- •gastrointestinal perforation
- •thrombophlebitis or hypercoagulable state
- •gastrointestinal obstruction and/or stricture
- •coronary artery disease (CAD)
- •significant atherosclerosis.
- •Current evidence of (within the past 6 months):
- •diverticulitis
- •symptomatic cholelithiasis
- •proctitis.
- •Current evidence of:
- •Hemoccult (+) stool.
- •6.The subject has a BMI of =27.
- •7.Mental impairment or inability or refusal to follow directions.
- •8.The subject has current evidence of, or has been treated for a malignancy within the past five years (other than localized basal cell, squamous cell skin cancer or cancer in situ that has been resected).
- •9.The subject exhibits evidence of hepatic dysfunction, viral hepatitis, or exhibits serum ALT (SGPT), AST (SGOT) values >2.5 times the upper limit of normal or alkaline phosphatase or bilirubin values >2.0 times the upper limit of normal.
- •10.The subject displays renal impairment as evidenced by a serum creatinine value >2.0 mg/dl.
- •11.The subject has used any medication within the seven days prior to dosing, unless approved by the investigator and GSK personnel. Section 9.1.
- •12.The subject has used an investigational drug, or participated in an investigational study, within 30 days of the Screening Visit.
- •13.The subject has a history of drug allergies (including but not limited to hypersensitivity responses to a
研究者
相似试验
进行中（未招募）
1 期
Clinical study evaluating the effect of Amifampridine Phosphate in Ambulatory Patients with Spinal Muscular Atrophy (SMA) Type 3.EUCTR2017-004600-22-ITCATALYST PHARMACEUTICALS INC.12
招募中
2 期
The effects of two doses of alcohol on eye movement behaviour during drivingeurologicalNeurologicalNeurological - Other neurological disordersACTRN12623000528651Swinburne University of Technology30
招募中
2 期
The effects of alcohol on eye movement behaviour during drivingeurologicalNeurologicalEye - Normal eye development and functionNeurological - Studies of the normal brain and nervous systemACTRN12623001255673Swinburne University of Technology30
已完成
2 期
Placebo controlled,randomised,crossover study of the efficacy of dipyridamole in the management of angina in patients with Coronary Slow Flow PhenomenoCoronary Slow Flow PhenomenonCardiovascular - Other cardiovascular diseasesACTRN12606000236594The Queen Elizabeth Hospital,Cardiology Unit16
已完成
不适用
A Randomized, Placebo-Controlled Crossover Study to Evaluate the Effect of Veliparib (ABT-888) on Cardiac Repolarization in Subjects with Relapsed or Refractory Solid Tumorssolid tumors10027655cancerNL-OMON40461AbbVie B.V.16